Drug
Alirocumab Sar236553
Alirocumab Sar236553: highest development phase Phase 1, developed by Sanofi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| alirocumab SAR236553 (REGN727) NCT01670734 | Phase 1 | Hypercholesterolemia |
Latest
No recent events.
Follow Alirocumab Sar236553 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.